Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Autor:	Elizabeth R. Packnett, Isabelle H. Winer, Abiola Oladapo, Matthew Wojdyla
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	respiratory syncytial virus respiratory tract infections infant premature pediatric hospitalization intensive care units pediatric Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950
Zdroj:	Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Druh dokumentu:	article
ISSN:	2164-5515 2164-554X 21645515
DOI:	10.1080/21645515.2023.2252289
Popis:	Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended in preterm infants born at 29 weeks gestational age (wGA) or later. This study’s objective was to describe RSVH risk and severity in preterm infants (29–34 wGA) without comorbidities relative to healthy term infants and to each other by gestational age. Using the MarketScan Multi-State Medicaid and Commercial Databases, infants born from July 1, 2014 to June 30, 2019, at 29–34 wGA (preterm) and >37 wGA (term) were identified. During RSV seasons (November to March) from 2014 to 2020, claims incurred by infants while they were
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/2a2de03e79f148b6ad3b812d310abfe8 Zobrazit plný text záznamu View record in DOAJ